Dr. Nasta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
Fl 12South PCAM
Philadelphia, PA 19104Phone+1 215-662-3933Fax+1 215-615-5887
Summary
- Dr. Sunita Nasta is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania. She received her medical degree from Virginia Commonwealth University School of Medicine with residency training at Baylor Collegand has been in practice 22 years. She specializes in hematologic oncology and is experienced in non-hodgkin lymphoma, hematologic oncology, t-cell lymphomas, hodgkin's lymphoma, and clinical research.
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
- Baylor College of MedicineResidency, Internal Medicine, 1995 - 1998
- Virginia Commonwealth University School of MedicineClass of 1995
- Stanford UniversityBS, Micrbiology/Immunology, Research honors, 1987 - 1991
Certifications & Licensure
- PA State Medical License 2001 - 2024
- TX State Medical License 1997 - 2003
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
Roles: Principal Investigator, Contact
- CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Start of enrollment: 2021 May 26
Roles: Contact
Publications & Presentations
PubMed
- Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP.Vincent Ni, Sunita D Nasta, Stefan K Barta, Stephen J Schuster, Elise A Chong
Haematologica. 2024-11-28 - Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome.Omar Elghawy, Austin G Yang, Jonathan H Sussman, Colin J Thomas, Jordan S Carter
Journal of the American Academy of Dermatology. 2024-11-16 - Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression.Daniel J Landsburg, Jennifer J D Morrissette, Sunita D Nasta, Stefan K Barta, Stephen J Schuster
Cancer Research Communications. 2024-11-01
Journal Articles
- Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care WorkersMatthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine
- International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman DiseaseAaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
- Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin LymphomaStephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood
Abstracts/Posters
- Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma PatientsSunita Dwivedy Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell PrecursorsSunita D Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC RearrangementSunita Dwivedy Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- OncLive® Presents State of the Science Summit™ on the Treatment of Hematologic MalignanciesSeptember 10th, 2019
- Treatment Doctor Tested on Himself Can Put Others into RemissionAugust 13th, 2019
- Expert Emphasizes Appropriate Diagnosis, Staging of T-cell LymphomasNovember 30th, 2017
Committees
- Chair, Clinical Trials Scientific Monitoring Committee 2015 - Present
Professional Memberships
- Member
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: